Foamix Pharmaceuticals Topical Antibiotic Foam

[Guide]

Foamix Pharmaceuticals Ltd. is a clinical-stage pharmaceutical company. The Company is engaged in the development and commercialization of foam-based formulations, using its technology, which includes its foam platforms. It is focused on developing and commercializing its minocycline foam for the treatment of acne, rosacea and other skin conditions. Its product candidates include FMX101, FMX102, FMX103 and FDX104. Its lead product candidate, FMX101, is a topical foam formulation of the antibiotic minocycline for the treatment of moderate-to-severe acne. FMX102 is a formulation of its minocycline foam being developed for the treatment of impetigo. FMX103 is a topical foam formulation of minocycline for the treatment of moderate-to-severe Papulopustular rosacea. FDX104 is a topical foam formulation of the antibiotic doxycycline for the treatment of severe acne-like rashes induced by chemotherapy. It has conducted one Phase II clinical trial for each of FMX101, FMX102, FMX103 and FDX104.

Head-To-Head Comparison: Foamix Pharmaceuticals (FOMX) versus Its Competitors, Posted by Anthony Sawyer, Week Herald

Topical Minocycline Foam FXFM244 apparently was terminated. 

For the latest update

[Guide]

"The firm is also developing FMX103, a version of its minocycline foam FMX101, which is in Phase II clinical trial for the treatment of rosacea."

Foamix Pharmaceuticals (NASDAQ:FOMX) Covered By Yet Another Research Firm
December 7, 2017 - By Clifton Ray, Weekly Hub

[Guide]

Update 

"In the assessment of facial dermal tolerability at Week 52, more than 95% of patients had either no signs or symptoms, or signs/symptoms that were classified “mild” (burning/stinging, flushing/blushing, dryness, itching, peeling and hyperpigmentation). The severity of key clinical manifestations of rosacea - erythema and telangiectasia - had both significantly improved when compared to Baseline of the preceding double-blind studies. Patient satisfaction with FMX103 treatment remained high when re-assessed at Week 52 which was consistent with scores obtained at Week 12 (end of double-blind studies)."

Foamix Announces Positive Results from Phase 3 Open-Label Safety Study Evaluating FMX103 Topical Minocycline Foam for Treatment up to 1 Year
Long Term Data on FMX103 Demonstrated a Generally Favorable Safety Profile; 81.6% of Patients Achieved Clear or Almost Clear Skin at 52 Weeks
Global Newswire

Foamix Announces Dosing of Last Patient in Phase 3 Rosacea Studies for Minocycline Foam FMX103

For the latest update